Yun Zhang

Dr. Yun Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
YHYanfang Huang
Yanfang Huang
SLSijia Li
Sijia Li
XLXiuli Lu
Xiuli Lu
CWChen Wei-Qiang
Chen Wei-Qiang
YZYun Zhang
Yun Zhang
Background: Chronic diseases significantly impact global morbidity and mortality, affecting millions. Self-management interventions are crucial for improving patient health outcomes. This study explores the effects of self-management interventions on the quality of life (QOL), self-efficacy, depression, and anxiety of patients with chronic diseases. Methods: Relevant studies were searched from PubMed, EMBASE, and Web of Science. Two reviewers independently screened the literature, evaluated the risk of bias assessment, and extracted characteristics and outcomes among patients with chronic diseases. For each included study, we calculated the standardized mean difference (SMD) and 95% confidence interval (CI) of the main outcomes. When deemed feasible, the heterogeneity of the study was explored by meta-analysis and subgroup analysis. Results: Thirty-four studies involving a total of 7603 patients with chronic diseases were included. Self-management interventions significantly improved quality of life (Higher-better QOL and Lower-better QOL), self-efficacy, and reduced depression symptoms compared to usual care (95%CI 0.01 to 0.15, p = 0.03; 95%CI −0.49 to −0.08, p = 0.006; 95%CI 0.19 to 0.62, p < 0.001; 95%CI −0.23 to −0.07, p < 0.001). However, no significant effect was found for anxiety (95%CI −0.18 to 0.03, p = 0.18). In the heterogeneity analysis, Lower-better QOL and self-efficacy were all higher than 50% (I2 = 80%, 87%). After the subgroup analysis, the heterogeneity of Lower-better QOL and self-efficacy was less than 50% (I2 = 0%, 16.1%). Subgroup analyses revealed that studies with mean age greater than 60 years old and follow-up times greater than 6 months were more effective in improving patients’ Lower-better QOL (p = 0.03, p = 0.004), whereas follow-up times less than 6 months were better at reducing patients’ anxiety symptoms (p = 0.03). Conclusions: Self-management interventions are more effective than routine care in managing chronic diseases, significantly improving patients’ quality of life, self-efficacy, and reducing depressive symptoms, but they did not show significant improvements in anxiety symptoms. Overall, self-management interventions for chronic diseases can help patients adapt to the changes brought about by the disease and self-manage diseases to prevent disease progression.

Verified
Journal Article
Open access
PDF file
YHYanfang Huang
Yanfang Huang
SLSijia Li
Sijia Li
JPJinghua Pan
Jinghua Pan
CSCongjing Song
Congjing Song
CWChen Wei-Qiang
Chen Wei-Qiang
YZYun Zhang
Yun Zhang
Ultraviolet radiation (UVR) has various effects on human cells and tissues, which can lead to a variety of skin diseases and cause inconvenience to people’s lives. Among them, solar dermatitis is one of the important risk factors for malignant melanoma, so prevention and treatment of solar dermatitis is very necessary. Additionally, liquiritin (LQ) has anti-inflammatory effects. In this study, we aimed to evaluate the anti-inflammatory and pro-wound healing effects of liquiritin carbomer gel cold paste (LQ-CG-CP) in vitro and in vivo. The results of MTT experiments showed no cytotoxicity of LQ at concentrations of 40 μg/mL and below and cell damage at UVB irradiation doses above 60 mJ/cm2. Moreover, LQ can promote cell migration. ELISA results also showed that LQ inhibited the elevation of the inflammatory factors tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) after UVB irradiation. In the mouse model of solar dermatitis, 2% LQ-CG-CP showed the best therapeutic efficacy for wound healing and relief of itching compared to MEIBAO moist burn moisturizer (MEBO). What is more, the results of skin histopathological examination show that LQ-CG-CP promotes re-epithelialization, shrinks wounds, and promotes collagen production, thus promoting wound healing. Simultaneously, LQ-CG-CP reduced TNF-α, IL-1β, and IL-6 expression. In addition, LQ-CG-CP was not observed to cause histopathological changes and blood biochemical abnormalities in mice. Overall, LQ-CG-CP has great potential for the treatment of solar dermatitis.

28 July 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YZYun Zhang
Yun Zhang
SLSijia Li
Sijia Li
YHYanfang Huang
Yanfang Huang
CSCongjing Song
Congjing Song
CWChen Wei-Qiang
Chen Wei-Qiang
YYYiling Yang
Yiling Yang
Glucocorticoids are often used and highly effective anti-inflammatory medications, but prolonged topical application may alter the epidermis’ normal structure and function, potentially resulting in a number of adverse effects. Topical glucocorticoid-induced skin inflammation is a dangerous condition that develops after topical glucocorticoid use. The patients become dependent on the medication and, even after the medication is stopped, the dermatitis symptoms recur, severely impairing their quality of life. Thus, the need to aggressively confront Topical glucocorticoid-induced skin inflammation is critical. Prior research has demonstrated that topical administration of licorice’s flavonoid component liquiritin stimulates epidermal proliferation, which in turn enhances the creation of collagen and the healing of wounds. Therefore, the purpose of this work was to determine if topical use of liquiritin carbomer gel can treat glucocorticoid-induced changes in mice skin epidermal function, and the mechanisms involved. The findings demonstrated that, in the mice model of topical glucocorticoid-induced skin inflammation, liquiritin carbomer gel aided in the restoration of skin barrier function. These outcomes may have been caused by enhanced expression of the proteins Aquaporin 3, Keratin 10, and Claudin-1, as well as the restoration of epidermal hyaluronan content. In the meantime, liquiritin carbomer gel dramatically decreased the expression of TNF-α, IL-1β, IL-6, IFN-γ, and IgE in mice, according to ELISA tests. Furthermore, topical treatment of liquiritin carbomer gel boosted the expression of superoxide dismutase, catalase, and decreased malondialdehyde expression, potentially counteracting the detrimental effects of glucocorticoids on the epidermis. In summary, these findings imply that topical liquiritin carbomer gel can treat glucocorticoid-induced skin damage through various mechanisms of action.

30 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
YZYun Zhang
Yun Zhang
XZXiao-Bin Zheng
Xiao-Bin Zheng
YHYan-Fang Huang
Yan-Fang Huang
SLSi-Jia Li
Si-Jia Li
XYXiao-Chun Yang
Xiao-Chun Yang
YYYi-Ling Yang
Yi-Ling Yang
Purpose The Breast Imaging Reporting and Data System (BI-RADS) and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET) have some limitations in the diagnosis of breast cancer. The extra domain B splice variant of fibronectin (EDB-FN), which is overexpressed in several cancer types, including breast cancer, is an approved diagnostic and therapeutic target of EDB-FN-positive cancers. Herein, we provide the EDB-FN-targeted peptide EDBp as a noninvasive oncological imaging modality for the molecular imaging of breast cancer.Procedures The binding of the peptide EDBp-Cy5 to EDB-positive breast cancer cells was investigated by flow cytometry and confocal microscopy. Near-Infrared Fluorescence (NIRF) imaging was performed at 48 hours after 1 µmol EDBp-Cy5 was intravenously injected into subcutaneous MDA-MB-231 breast cancer model mice or pulmonary metastasis model mice. Model mice were intravenously injected with approximately 100 µCi of [18F]-EDBp, and PET/CT scanning was performed after 2 hours of in vivo circulation.Results Our results demonstrate that EDBp-Cy5 had a strong binding ability to the MDA-MB-231 cells. EDBp-Cy5 exhibited specific tumor accumulation in MDA-MB-231 subcutaneous and pulmonary metastasis model mice. Importantly, we proposed and validated an EDBp peptide-based radiotracer [18F]-EDBp for PET imaging. [18F]-EDBp provided excellent diagnostic value for PET imaging of breast cancer, especially in subcutaneous tumors. The uptake of [18F]-EDBp in subcutaneous tumors (6.53 ± 0.89%, ID/g) was unexpectedly higher than that in the kidney (4.96 ± 0.20, %ID/g), which is the main metabolic organ of peptides. In the pulmonary metastasis model mice, PET/CT imaging showed that [18F]-EDBp moderately accumulated in the pulmonary metastases.Conclusion The high tumor uptake of this radiotracer in mice suggests its potential for application in PET imaging of EDB-FN-positive breast cancer for disease staging of regional and distant metastases and relapse monitoring.

14 April 2026 in Gels
Verified
Journal Article
Open access
PDF file
YZYun Zhang
Yun Zhang
QTQiqing Tan
Qiqing Tan
SLSijia Li
Sijia Li
XHXiangdi Hu
Xiangdi Hu
ALAoxiang Luo
Aoxiang Luo
MLMing Li
Ming Li
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dryness and itching. Steroids are the most common therapeutic agents, may induce skin atrophy, and damage the skin barrier. Therefore, we need to find a safer alternative option. Liquiritin (LQ), a flavonoid compound extracted from licorice rhizomes, possesses anticancer, anti-inflammatory, and antioxidant effects. This study aimed to investigate the therapeutic effects of LQ on AD, focusing on its potential skin barrier-protective and anti-inflammatory mechanisms. In this research, we prepared liquiritin carbomer gel (LQ-CG) and assessed its treatment effects on mice with AD triggered by 2,4-dinitrofluorobenzene (DNFB). It effectively attenuated AD progression by ameliorating skin lesions, decreasing epidermal thickness and mast cell infiltration, downregulating inflammatory cytokine levels, and restoring the expression of claudin-1, loricrin, and occludin. It also inhibited the release of TNF-α, IL-1β, and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, and showed no significant toxicity to major organs in mice. In summary, our findings demonstrate that LQ-CG can effectively alleviate atopic symptoms by repairing the skin barrier and inhibiting inflammatory responses without causing significant changes in organ indices